[The PROMISE study : confirmation of effectiveness of benralizumab in severe eosinophilic asthmatic patients].

Benralizumab is a monoclonal antibody directed toward the α subunit of the interleukin-5 receptor. This drug has been established as a key treatment for severe hypereosinophilic asthma. Here we report results of the PROMISE study, an observational study conducted in 73 severe asthmatic patients treated at the asthma clinic of CHU Liège and whose blood eosinophil count was > 300/µl. After 6 months of treatment, benralizumab reduced exacerbation rate by 92 % and oral corticoid maintenance dose by 83 %, and significantly improved asthma control and quality of life. These effects were maintained over a 18-month time period. These clinical effects were associated with blood and airway depletion in eosinophils but not with a reduction in FeNO (fractional exhaled nitric oxide). The PROMISE study confirms the effectiveness of benralizumab in severe eosinophilic asthmatic patients.